2023 年第一季度报告 证券代码：603087 证券简称：甘李药业 甘李药业股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人（会计主管人员）周丽保证季度 报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 1 / 14 2023 年第一季度报告 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |----------------------------|------------------------------|-------------------|--------------------------------|--------------------------------- ...

2022 年年度报告 公司代码：603087 公司简称：甘李药业 甘李药业股份有限公司 2022 年年度报告 1 / 191 2022 年年度报告 致投资者的一封信 ——星光不问赶路人，时光不负有心人 尊敬的各位投资者和朋友们： 岁序更替，华章日新。回首 2022 年，跌宕起伏，世界百年未有之大变局加速演进，国际地缘 政治格局与能源粮食冲突相互交织，演变加剧，世界经济增长不平衡、不确定性增大，整体经济 形势曲折前行。在这深刻多变的一年里，各项难题和挑战没有动摇我们坚强的意志，前方的迷雾 没有阻断我们前进的步伐，反而使我们更加坚定和强大。 中国有 14 多亿人口，随着经济的不断发展和人口老龄化趋势的不断加深，大家对药品和治疗 方法都有着多样化的新需求，并且在变化中日益增长。如何解决社会中具有挑战性的健康问题， 做高质量、高标准、值得信赖的好药，为患者、医务工作者和医疗保障体系提供更优价值的治疗 选择，同时，降低治疗成本，让大家生活得更长久、更健康，是我们一直以来不断奋斗和坚持的 方向。 近年来，为减轻患者看病用药的负担，国家积极推行药品和高值医用耗材的集中带量采购， 其中胰岛素集采对患者和生物医药行业发展影响深 ...

Financial Performance - In the first half of 2022, the company achieved revenue of 835 million CNY, a year-on-year decrease of 43.42%, and a net profit attributable to shareholders of -198 million CNY[2]. - The company's operating revenue for the first half of 2022 was ¥834,799,215.95, a decrease of 43.42% compared to ¥1,475,429,759.92 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was -¥197,607,134.96, representing a decline of 153.01% from ¥372,769,630.83 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥208,858,516.23, down 161.45% from ¥339,870,808.38 in the same period last year[18]. - The net cash flow from operating activities was ¥281,247,985.16, a decrease of 36.94% compared to ¥445,995,750.73 in the previous year[18]. - The company's revenue decreased significantly due to the impact of the insulin centralized procurement results, leading to a decline in product prices[32]. - The company reported a total comprehensive loss of approximately ¥193.60 million for the first half of 2022, compared to a comprehensive income of ¥370.57 million in the same period of 2021[95]. Research and Development - Research and development investment reached 319.51 million CNY, accounting for 38.27% of sales revenue, with a year-on-year increase of 28.36%[3]. - The company completed the first human dosing in the Phase I clinical trial of its innovative GLP-1 analog GZR18 in the U.S. and China[4]. - The company is actively investing in research areas including chemical drugs, protein engineering, oncology, and cardiovascular diseases[22]. - The company is focusing on advanced research projects in diabetes and related fields to mitigate the risk of new product substitution[58]. - The company has a strong R&D team, with nearly 60% holding master's or doctoral degrees, and is enhancing its capabilities through partnerships with top universities[33]. Product Development and Market Strategy - The company plans to submit marketing authorization applications for its insulin products to the FDA and EMA, marking a significant step in its internationalization strategy[4]. - The company aims to expand its product line in diabetes diagnosis and treatment, enhancing its market competitiveness[22]. - The company has launched its first oral hypoglycemic drug, Phosphate Sitagliptin Tablets, which will enhance its competitiveness in the DPP-4 inhibitor market[30]. - The company is actively developing the fourth generation of insulin and other advanced diabetes treatments, with ongoing projects including GZR101, GZR4, and GZR18[30]. - The company has established a comprehensive product line covering long-acting, rapid-acting, and premixed insulin, with five insulin analogs and one human insulin product currently on the market[30]. Market Expansion and Procurement - The company secured a total procurement volume of 35.34 million insulin units in the first year of the procurement agreement, covering over 21,000 medical institutions[2]. - The company aims to leverage its high-ranking procurement results to rapidly increase market share in the upcoming year[2]. - The implementation of the insulin centralized procurement policy is expected to significantly reduce patient medication costs and reshape the competitive landscape of the insulin industry[26]. - The company achieved high-ranking bids for all six insulin products in the centralized procurement, aligning with the DRG/DIP payment reform direction, which encourages the selection of cost-effective products by medical institutions[26]. - The company is strategically positioning itself in the primary healthcare market to enhance its brand image among family doctors and increase its drug usage in initial consultations[26]. Financial Management and Investments - The company is implementing a cost leadership strategy by optimizing production processes and enhancing cost control across the entire supply chain[34]. - The company plans to enhance R&D investment and product pipeline in response to insulin procurement policies[55]. - The company aims to diversify its product structure to mitigate risks associated with reliance on insulin sales[56]. - The company is actively pursuing international clinical trials and market expansion to create new profit growth points[56]. - The company has received FDA approval for its first product, a single-use injection pen needle, which supports its global market expansion strategy[35]. Environmental and Governance Practices - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating its commitment to sustainable practices[64]. - The company has implemented low-nitrogen combustion technology in its boilers to ensure compliance with nitrogen oxide emission standards[66]. - The company has established a comprehensive emergency plan for sudden environmental incidents, filed with the local ecological environment bureau[69]. - The company has committed to resolving land ownership issues and competition in the industry, with long-term effectiveness of these commitments[74]. - The company has appointed new independent directors and management personnel as part of its governance restructuring[61]. Shareholder and Equity Information - The company reported a total share capital of 561,540,000 shares, with 48.62% being restricted shares and 51.38% being unrestricted shares[82]. - The largest shareholder, Gan Zhongru, holds 177,135,207 shares, representing 31.54% of the total shares[85]. - Major shareholders have pledged to limit their annual stock transfers to no more than 25% of their total holdings during their tenure and will not transfer shares within six months post-departure[75]. - The company has committed that any stock reduction by major shareholders will not occur below the initial public offering price, with a lock-up period extending if stock prices fall below this threshold[75]. - The company has not proposed any profit distribution or capital reserve increase plans for the half-year period[63].